NKGen Biotech, Inc. Common Stock (NKGN) Research

NKGen Biotech, Inc., a biotechnology company in the clinical trial phase, was established in 2017 and has its headquarters in Santa Ana, California. This company is dedicated to creating and marketing cutting-edge cell therapies, specifically those derived from activated natural killer (NK) cells, to address both neurodegenerative and cancer-related illnesses within the United States. Its product pipeline features SNK01, an autologous NK cell therapy candidate currently undergoing Phase I/IIa clinical evaluation for neurological disorders such as Alzheimer's and Parkinson's disease. Additionally, the company is advancing SNK02, which comprises two distinct therapies: an allogeneic NK cell therapy that has successfully concluded Phase 1 trials, and a HER2-CAR NK cell therapy candidate that remains in preclinical development, both targeting challenging solid tumors. NKGen Biotech has formed a strategic alliance with HekaBio K.K., a Japanese healthcare platform. This partnership aims to cover the entire process – from development and clinical studies to securing regulatory approvals, manufacturing, and commercializing NKGen's autologous NK cell therapies for central nervous system and autoimmune conditions across Japan. The company also holds a licensing agreement with NKMAX Co., Ltd. to further the research and development of its natural killer cell initiatives.

Open NKGen Biotech, Inc. Common Stock (NKGN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.